+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07502508

Randomized Trial of Icovamenib Added to GLP-1 Therapy for Adults With Type 2 Diabetes Not Meeting Blood Sugar Goals

Led by Biomea Fusion Inc. · Updated on 2026-10-20

60

Participants Needed

20

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of icovamenib in adults with Type 2 Diabetes T2D who are not meeting blood sugar targets despite using GLP-1-based therapy. This phase 2 randomized, double-blind, placebo-controlled trial focuses on participants who have been treated with GLP-1 for at least three months but still have elevated HbA1c levels above the target set by the American Diabetes Association. Participants will be randomly assigned to receive either icovamenib 100 mg once daily or a matching placebo, alongside their current GLP-1 or GIPGLP-1 receptor agonist regimen. This treatment phase lasts for 12 weeks. Afterward, all participants continue on a stable dose of their baseline GLP-1-based therapy, such as Ozempic, for the remainder of the study. The total trial duration is about 57 weeks, including screening and follow-up. Throughout the study, participants will undergo regular evaluations including blood tests to measure HbA1c and monitor glycemic control. Researchers will track adherence to medication and assess safety and treatment effects during the 12-week treatment period and follow-up. The main goal is to determine if icovamenib improves blood sugar control better than placebo over 26 weeks, with the entire participation lasting nearly a year.

CONDITIONS

Brief Title

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Research Team

B

Biomea Fusion Inc.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here